Kornimate/medical-research-clean huggingface dataset:
swiss multiple sclerosis registry

Conditions: Multiple Sclerosis

Summary: the swiss multiple sclerosis registry is a national, patient-centered registry with the aim to document the epidemiology of multiple sclerosis (ms), as well as the quality of life of persons living with ms in switzerland.

the swiss multiple sclerosis registry is a national, patient-centered research project with the aim to document the epidemiology of multiple sclerosis (ms), as well as the quality of life of persons living with ms in switzerland. the swiss ms registry pursues a "citizen science" approach, that is, persons with ms are not just study participants but also act as ms experts and are active contributors to the interdisciplinary swiss ms registry research network. initiated and funded by the swiss ms society, the swiss ms registry represents a collaborative effort by numerous ms caregivers, researchers and persons with ms. it is hosted by the epidemiology, biostatistics and prevention institute at the university of zurich. how many ms-affected persons are living in switzerland and how are they coping with ms in their daily lives? what is the current situation with regard to access to and use of drug and non-drug treatments for ms? these and other questions are addressed by means of semi-annual surveys. further research activities concern the quality of life of persons with ms, mobility, personal resources and support by friends and family, work situation, mental health, clinical progression of ms, as well as alternative therapies. owing to a flexible study design, participants can decide between different levels of commitment (from one-time surveys to repeated, semiannual surveys and medical records review). furthermore, study participants receive summaries of their data as charts and tables. data collection primarily occurs via a newly designed online platform, but paper-and-pencil questionnaires are also available. as an additional incentive, the online platform includes a diary with basic capabilities for analyses and printing.

Eligibility criteria:
inclusion criteria: * persons with a confirmed multiple sclerosis diagnosis * 18 years and older * living in switzerland or receiving ms care in switzerland exclusion criteria: * younger than 18 years * not living in switzerland and not receiving ms care in switzerland

Keywords: multiple sclerosis treatment quality of life symptoms
a clinical study of ak120 in adolescents with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a randomized double-blind, placebo-controlled, multicenter phase iii clinical study evaluating the efficacy and safety of ak120 in the treatment of moderate-to-severe ad in adolescents.

this is a randomized double-blind, placebo-controlled, multicenter phase iii clinical study to evaluate the safety and efficacy of ak120 in the treatment of moderate-to-severe ad in adolescents. the total duration of the study planned is approximately 57 weeks.

Eligibility criteria:
inclusion criteria: * male or female subjects aged ≥12\<18 years old, weight ≥ 30kg. * ad diagnosed at least half a year before screening. * subject with easi score ≥16, iga ≥ 3, bsa ≥ 10% at screening and baseline * daily peak p-nrs scores (weekly average) at baseline visit ≥ 4. exclusion criteria: * acute onset of ad in 4 weeks prior to enrollment. * undergone or planned surgery during the study period within the 4 weeks prior to enrollment, or unable to fully recover from surgery before enrollment. * previously suffered from vernal keratoconjunctivitis (vkc) or atopic keratoconjunctivitis (akc). * received systemic traditional chinese medicine treatment within the 4 weeks before randomization or topical traditional chinese medicine treatment within 1 week before randomization. * received treatment with other clinical study drugs within 4 weeks or 5 halflives before randomization (whichever is longer). * have a history of allergies to any component of ak120 and/or severe allergic reactions to monoclonal antibodies.
reducing nephrotoxicity of vancomycin: a prospective study of continuous versus intermittent infusion of vancomycin

Conditions: Infections Requiring Prolonged Duration (>10 Days) of Vancomycin

Summary: this study is being carried out to find out whether there is reduction in vancomycin-induced kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous infusion. this study will recruit 220 subjects from 2 hospitals over a period of 3 years. participants are invited if they have an infection that requires prolonged vancomycin therapy (\> more than 10 days).


Eligibility criteria:
inclusion criteria: * adults aged 21-80 years * documented infection requiring prolonged (\> 10 days) of vancomycin therapy * creatinine clearance \> 50 ml/min (using cockroft-gault equation) exclusion criteria: * patient already received 7 days or more of vancomycin therapy * pregnancy * severe burns \> 40% body surface area * spinal cord injuries * participation in another interventional trial in previous 30 days * inability to obtain informed consent
sensitivity training for parents with premature infants

Conditions: Premature Birth

Summary: this study evaluated the effectiveness of a culturally adapted version of the mother-infant transaction program (mitp) among chinese mothers with premature infants in public hospitals in hong kong.

potential participants at two public hospitals in hong kong were identified by ward nurses. mother-infant dyads with infants born at 36 weeks or earlier were assessed for eligibility. data collection was conducted after obtaining written consent from the mothers. mother-infant dyads who met the inclusion criteria were randomly allocated to either the intervention or the treatment-as-usual control group. each dyad was assessed at six time points, i.e., baseline, immediately after intervention/tau, and when the infants were at the gestation-corrected ages of 3, 6, 9, and 12 months.

Eligibility criteria:
inclusion criteria: * mothers with premature infants born at 36 weeks or earlier exclusion criteria: * insufficient spoken and written chinese ability of the mother * mother under 18 years of age * triplets or higher multiples * infants with congenital abnormalities (e.g., metabolic disorder, chromosomal disorder)

Keywords: sensitivity training mother-infant interaction
stem cells for uremic calciphylaxis patients

Conditions: Chronic Kidney Diseases; Calciphylaxis; Calcific Uremic Arteriolopathy; Treatment

Summary: treatment for uremic calciphylaxis patients with human amniotic mesenchymal stem cells

calciphylaxis is a rare, devastating disorder causing excruciatingly painful ischemic skin lesions. sepsis due to the infection of ulcerated wounds is a common cause of death. to date, practical therapies typically include wound care, pain management, anti-infection and aggressive treatment of predisposing conditions. drugs such as sodium thiosulfate, bisphosphonate, and cinacalcet are also suggested. however, it's still a lethal disease with 1-year mortality up to 80% for dialysis patients. here the investigators plan to treat uremic calciphylaxis patients with human amniotic mesenchymal stem cells (hamscs).

Eligibility criteria:
inclusion criteria: 1. 18-60 years old. 2. patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis). 3. clinical diagnosis of calciphylaxis. 4. all subjects signed informed consent. exclusion criteria: 1. patients who refuse to sign informed consent. 2. patients with malignant tumor or serious mental disease, cardiovascular disease, shock, abnormal liver function and secondary kidney disease. 3. pregnant or lactating women of childbearing age. 4. participation in another clinical trial with an experimental drug within 90 days prior the inclusion.

Keywords: chronic kidney diseases calciphylaxis calcific uremic arteriolopathy human amniotic mesenchymal stem cells rare disease (orpha280062)
a study in healthy men to test how different doses of bi 3031185 are tolerated and how food influences the amount of bi 3031185 in the blood

Conditions: Healthy

Summary: this trial starts the clinical development of bi 3031185. the single rising dose (srd) part of the trial investigates safety, tolerability, and pharmacokinetics of a range of single doses of bi 3031185 as basis for further development. the food effect (fe) part is conducted to assess the effect of food on the relative bioavailability of the bi 3031185 tablet formulation.


Eligibility criteria:
inclusion criteria: * healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (bp), pulse rate (pr)), 12-lead electrocardiogram (ecg), and clinical laboratory tests without any clinically significant abnormalities * age of 18 to 45 years (inclusive) * body mass index (bmi) of 18.5 to 29.9 kg/m2 (inclusive) * signed and dated written informed consent in accordance with international council for harmonisation-good clinical practice (ich-gcp) and local legislation prior to admission to the trial exclusion criteria: * any finding in the medical examination (including bp, pr or ecg) deviating from normal and assessed as clinically relevant by the investigator * repeated measurement of systolic blood pressure outside the range of 90 to 139 millimetre(s) of mercury (mmhg), diastolic blood pressure outside the range of 50 to 89 mmhg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) * any laboratory value outside the reference range that the investigator considers to be of clinical relevance * any evidence of a concomitant disease. this does not include acceptable concomitant conditions that were not assessed as clinically relevant by the investigator (e.g. possible cases of myopia, hyperopia, astigmatism, non-active pollinosis, or mild acne of the skin) * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders * cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) * diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders * history of relevant orthostatic hypotension, fainting spells, or blackouts further exclusion criteria apply.
transperineal ultrasonography and premature rupture of membranes

Conditions: Preterm Premature Rupture of the Membranes

Summary: this study's aim is to evaluate diagnostic accuracy of transperineal ultrasound assessment compared with speculum examination, nitrazine and placental micro globulin-1 tests.

women with early and late preterm pregnancies with a complaint of fluid leakage are enrolled in the study. prior to speculum examination, sagittal view of the birth canal and transverse view of cervix and fornices are obtained with transperineal technique and images are stored. then speculum examination for pooling, nitrazine test and placental microglobulin-1 tests are performed and results are recorded. ultrasound images are analysed by an observer blind to physical examination findings. hypoechogenic fluid appearance of adequate size around the cervix and in the fornices are considered positive. placental microglobulin-1 test is used as reference. sensitivity and specificity values are calculated for each test.

Eligibility criteria:
inclusion criteria: * women with early and late preterm pregnancies, (i.e., women above 24th and below 37th week of gestation) * pregnant women with a complaint of fluid leakage exclusion criteria: * women with term pregnancies (i.e., women above 37th week of gestation) * women with unviable pregnancies (i.e., women below 24th week of gestation) * women in active labor (i.e., cervical dilatation above 4cm during admission) * women with vaginal bleeding
ambu aura gaintm guided vs non guided in edentulous ambu aura gaintm without gastric tube in endontolous patient

Conditions: Oropharyngeal Leak Pressure

Summary: the ambu® aura gaintm is a relatively new 2nd generation supraglottic airway device (sga) with a second port, providing gastric access to drain gastric content and air and it has an intergrated bite-block that helps avoiding rotation of the sga. it has been described and it is known from daily routine, that sga in edentulous patient provide inferior oropharyngeal leak pressure (olp). the aim of the study is to evaluate if the placement of a gastric tube through the second orifice leads to better olp and lowers the number of intervention needed for replacing the sga. the study also evaluates the olp after 15 minutes and after 30 minutes.


Eligibility criteria:
inclusion criteria: * asa i - 3 * signed informed consent * age 18 - 90 years * edentolous (or partial) patients * patients scheduled for elective surgery exclusion criteria: * patients with a known or predicted difficult airway * patients with anatomical disorders in the upper airway, the oesophagus or the trachea * patients at risk for aspiration * body mass index (bmi) \> 40 kg/m2
a modified approach for the closure of oral sinus communications

Conditions: Surgery Site Fistula

Summary: the aim of this study is to describe a modified surgical approach for the closure of oral sinus communications, using a buccal trapezoidal flap combined with a connective pedicle flap rotated from the palate


Eligibility criteria:
inclusion criteria: * patient with diagnosis of oro-antral communication * patients with adequate radiographic status * patients who read and signed the informed consent * patients without periodontal disease * patients≥18 exclusion criteria: * pregnancy or breastfeeding patients * patients compliance and patients with mental disorders * patients with diabetes * patients with osteonecrosis * patients with head and neck cancer

Keywords: extraction oro-antral communication oro-antral fistula
impact of von willebrand factor-platelet aggregates in patients with type 2b disease

Conditions: Von Willebrand Disease, Type 2B

Summary: the working hypothesis is that patients with von willebrand disease-type 2b may have neurological symptoms due to the chronic formation of platelets/von willebrand factor aggregates. interestingly, several patients present nonspecific neurological symptoms (nystagmus, headaches, memory disorder, ...) which may be associated with cerebral microangiopathy and chronic microvessel inflammation secondary to von willebrand disease-type 2b due to chronic exposure to von willebrand factor-platelets complexes.

investigator will use an extensive series of neuropsychological tests that cover virtually all cognitive domains. a measurement of global cognitive function will be assessed by the mini mental state examination (mmse). the verbal memory function will be assessed by the rey auditory verbal learning test (ravlt). visuospatial memory will be administered by the rey's complex figure test (rcft). to evaluate speed of mental processes, stroop test (three subtasks), the paper and pencil memory scanning task (four subtasks), the symbol-digit substitution task will be used. to evaluate attention, the verbal series attention test (vsat) will be used. to register subjective cognitive failures investigator will administer the cognitive failures questionnaire (cfq). the neurological evaluation will be completed with 3t (tesla) magnetic resonance imaging (mri) with different mri sequences including t1 3d space, flair 3d , 3d swi (susceptibility weighted imaging) and 2d epi (echo planar imaging) to address the presence of cerebral small vessel disease. the presence of each of the four mri markers for cerebral small vessel disease (white matter hyperintensities, lacunes, cerebral microbleeds and perivascular spaces will be addressed.

Eligibility criteria:
inclusion criteria: * patients with type 2b disease * neurological signs * signature of inform consent exclusion criteria: * contraindication for mri * pregnant women * other hemorrhagic disease

Keywords: vwf type 2b von willebrand disease
variable frequency stimulation of subthalamic nucleus for freezing of gait in parkinson's disease

Conditions: Parkinson's Disease

Summary: this is the first study on the effect of the variable frequency stimulation (vfs) on freezing of gait (fog) in parkinson's disease (pd) patients with stn dbs. fog has responded poorly to high frequency stimulation (hfs) but can be alleviated by relatively vfs. this study would have significant clinical implications in the management of freezing of gait (fog) in these pd patients with subthalamic nucleus (stn) dbs. the investigators hypothesize that vfs could have better effect on fog than hfs and low frequency stimulation (lfs).

hfs of stn provides consistent, long-term improvement of the cardinal motor signs of pd, such as bradykinesia, tremor and rigidity. fog has responded poorly to hfs and tends to continue to deteriorate over time, but this can be alleviated by relatively lfs. evidence has indicated that lfs-stn can improve axial signs in some but not all pd patients, but most of them experienced loss of efficacy in the short term. then comes to the little improvement or even worse of tremor, rigidity and bradykinesia, which consists of the three main symptoms of parkinson's disease. thus even if axial problems could be solved by lfs in a long way, it could also be hard to tolerate by those patients. the effect of vfs on fog will be studied. the investigators hypothesize that vfs could have better effect on freezing of gait than hfs and lfs.

Eligibility criteria:
inclusion criteria: 1. patients were receiving bilateral stn stimulation for more than six months. 2. they were optimized on conventional hfs for control of tremors, rigidity and bradykinesia yet complained of freezing of gait. 3. subjects had an ability to walk at least 10 meters independently during on dbs condition. exclusion criteria: 1. gait disorders perceived by patients as a direct consequence of stn stimulation and not the primary disease. 2. any change in the hfs dbs settings, three months prior to participation in the study. 3. complete inability to walk despite assistance while dbs on. 4. subjects responding to reprogramming of chronic dbs settings (report improvement of freezing). 5. subjects could not tolerate prolonged off medication condition.

Keywords: dbs vfs fog
safety procedure pulmonary artery denervation in addition to pulmonary vein isolation combined with ganglionated plexi ablation in patients with persistent atrial fibrillation and pulmonary hypertension

Conditions: Atrial Fibrillation; Hypertension, Pulmonary; Heart Diseases; Arrhythmias, Cardiac; Pathologic Processes; Cardiovascular Diseases; Lung Diseases

Summary: some patients with a long history of af develops ph "reactive" type with an increase in pulmonary vascular resistance due to vasoconstriction or structural changes of the vascular wall. rfa pvi + rfa gp is the "gold standard" in the treatment of patients with persistent af, do not respond to optimal therapy. the rear area of the pulmonary artery bifurcation is adjacent to the roof and part of the front of the left atrium. in the projection of this area are ganglionic plexus of the left atrium, the sympathetic nerve fibers of the pulmonary artery and baroreceptors main pulmonary artery.recent studies have shown that radiofrequency denervation of the pulmonary artery improves the quality of life in patients with ph.


Eligibility criteria:
inclusion criteria: * patients with symptomatic, drug - refractory af ( inefficiency 1c or iii class antiarrhythmic drugs), history of af 6 months or more without the restoration of sinus rhythm. * mpap ≥25 mmhg * pcwp≥15 mmhg * pulmonary vascular resistance (pvr). the pvr =(mpap-pcwp)/ carbon monoxide\] \> 2.5 woods unit exclusion criteria: * left ventricular ejection fraction \<35% * diameter la\> 60 mm on transthoracic echocardiography in the "m" -mode or volume of la more than 140 ml * significant regurgitation at the mitral valve * uncorrected congenital heart disease * rfa pvi, rfa gp, padn in history * foregoing heart surgery * life expectancy less than 12 months * who group i, iii, iv, v pulmonary artery hypertension * tricuspid valve stenosis, pulmonary supravalve stenosis. * cancer * pregnancy * thromboembolism la history * hyperthyroidism.

Keywords: pulmonary hypertension atrial fibrillation pulmonary arterial denervation safety pulmonary arterial gp ablation
the influence of applying additional weight on crouch gait in children with spastic cerebral palsy

Conditions: Cerebral Palsy; Gait, Spastic; Motor Disorders; Functional Neurological Disorder

Summary: the purpose of this study was to investigate the effectiveness of applying additional weight in the improvement of the crouch gait pattern in children with spastic cerebral palsy.


Eligibility criteria:
inclusion criteria: the children who participated in the study, aged 12 - 15 years old, were diagnosed with spastic cerebral palsy, level iii according to the classification of the gmfcs. exclusion criteria: from the study, they were excluded: 1. children who have received botulinum toxin injection up to 3 months before, 2. children who have had selective rhizotomy surgery up to 1 year before, 3. children who have a baclofen pump, 4. children with uncontrolled epilepsy, 5. children with cognitive deficits who cannot follow verbal instructions.

Keywords: cerebral palsy crouch gait physiotherapy balance kinematic analysis
gamma entrainment improve the recovery of awareness

Conditions: Disorder of Consciousness

Summary: the purpose of this study is to elucidate the occurrence of gamma entrainment and optimize the acousto-optic stimulation parameters to induce it in patients with disorders of consciousness (doc), to explore the prognostic value of gamma entrainment in patients with doc, and to clarify the effect of gamma entrainment on the recovery of awareness in doc patients. this study is divided into three parts. the first and third parts are prospective cohort studies, the second part is a randomized cross control study. we recruit doc patients, including vegetative state/unresponsive wakefulness syndrome (vs/uws) or minimally conscious state (mcs). the patients receive sound and light stimulation in the gamma band, and the changes of eeg are observed simultaneously to explore the occurrence of gamma entrainment. meanwhile, the changes of clinical behavior of patients before and after stimulation are evaluated.


Eligibility criteria:
inclusion criteria: age 16-80 years; clinical diagnosis of vs/uws or mcs according to the crs-r score within one week after admission; time post-onset \> 28 days. exclusion criteria: previous history of acquired brain injury or psychiatric or neurodegenerative diseases; clinical diagnosis of epilepsy; visual or auditory pathway damage; life threatening comorbidity, coexisting neoplasms, severe organ dysfunction, or unstable clinical condition (e.g., hemodynamic instability or severe respiratory failure); incomplete clinical data.